Pollen Allergy - Pipeline Review, H2 2015

Published: September 2015
No. of Pages: 106
   

Global Markets Direct’s, ‘Pollen Allergy - Pipeline Review, H2 2015’, provides an overview of the Pollen Allergy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pollen Allergy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pollen Allergy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pollen Allergy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pollen Allergy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pollen Allergy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Pollen Allergy - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Pollen Allergy Overview 10
Therapeutics Development 11
Pipeline Products for Pollen Allergy - Overview 11
Pipeline Products for Pollen Allergy - Comparative Analysis 12
Pollen Allergy - Therapeutics under Development by Companies 13
Pollen Allergy - Therapeutics under Investigation by Universities/Institutes 14
Pollen Allergy - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Pollen Allergy - Products under Development by Companies 18
Pollen Allergy - Products under Investigation by Universities/Institutes 20
Pollen Allergy - Companies Involved in Therapeutics Development 21
ALK-Abello A/S 21
Allergopharma Joachim Ganzer KG 22
Allergy Therapeutics Plc 23
Anergis SA 24
Biomay AG 25
BioTech Tools s.a. 26
Circassia Pharmaceuticals Plc 27
HAL Allergy BV 28
Immunomic Therapeutics, Inc. 29
Japan Tobacco Inc. 30
Laboratorios LETI S.L. 31
REGiMMUNE Corporation 32
Roxall Medizin GmbH 33
Shionogi & Co., Ltd. 34
Stallergenes S.A. 35
Pollen Allergy - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
AllerG - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Allergen Extract for Grass Pollen Allergy, Asthma and Allergic Rhino-Conjunctivitis - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
AllerJ - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
AllerT - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ASP-4070 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Birch-SPIRE - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
BM-31 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
BM-32 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
clustoid wiesenlieschgras - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Drugs for Cedar Pollen Allergy - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
gp-ASIT - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
grass hypoallergenic vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
japanese cedar hypoallergenic vaccine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
JCC-LAMP-Vax - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
MC-LAMP-Vax - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Multi-LAMP-Vax - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
PL-102 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Pollinex Quattro Grass - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Pollinex Quattro Japanese Cedar - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Pollinex Quattro Tree - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
rBet v1 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
rBet v1-FV - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
RGI-1001 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
S-555739 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
STG-210 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Timothy Grass Pollen Allergen Extract - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
TO-206 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Vaccine for Asthma, Grass Pollen Allergy and Allergic Rhino-Conjunctivitis - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Vaccine for Cedar Pollen Allergy - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Vaccine for Cedar Pollen Allergy - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Pollen Allergy - Recent Pipeline Updates 87
Pollen Allergy - Dormant Projects 96
Pollen Allergy - Discontinued Products 98
Pollen Allergy - Product Development Milestones 99
Featured News & Press Releases 99
Sep 01, 2015: First patient recruited in Pollinex Quattro Birch dose ranging study in Germany and Austria 99
Jun 03, 2015: Positive phase IIb data on BM32, Biomay''s innovative grass pollen allergy vaccine will be reported in hot topic session at major international scientific conference. 99
Apr 01, 2015: Anergis Announces Completion of Treatment in AllerT Phase II Dose-Ranging Trial 100
Mar 10, 2015: Positive Outcome of the PURETHAL Birch RUSH Study Results in an Approved, Accelerated up-dosing Regimen 100
Mar 09, 2015: Immunomic Therapeutics to Present at BIO-Europe Annual Conference 101
Feb 23, 2015: Anergis Presents Sustained Efficacy Data from its AllerT Phase IIb Trial at the AAAAI Annual Meeting 101
Feb 20, 2015: Immunomic Therapeutics to Present Data on Its Proprietary LAMP Vaccine Platform at 2015 American Academy of Allergy, Asthma and Immunology Meeting 102
Jan 28, 2015: Biomay reports positive Phase IIb data with the innovative 3rd generation grass pollen allergy vaccine BM32 102
Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT 103
Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT 104
Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 105
Contact Us 105
Disclaimer 106

List of Tables

Number of Products under Development for Pollen Allergy, H2 2015 11
Number of Products under Development for Pollen Allergy - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 13
Number of Products under Investigation by Universities/Institutes, H2 2015 14
Comparative Analysis by Late Stage Development, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Products under Development by Companies, H2 2015 18
Products under Development by Companies, H2 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H2 2015 20
Pollen Allergy - Pipeline by ALK-Abello A/S, H2 2015 21
Pollen Allergy - Pipeline by Allergopharma Joachim Ganzer KG, H2 2015 22
Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H2 2015 23
Pollen Allergy - Pipeline by Anergis SA, H2 2015 24
Pollen Allergy - Pipeline by Biomay AG, H2 2015 25
Pollen Allergy - Pipeline by BioTech Tools s.a., H2 2015 26
Pollen Allergy - Pipeline by Circassia Pharmaceuticals Plc, H2 2015 27
Pollen Allergy - Pipeline by HAL Allergy BV, H2 2015 28
Pollen Allergy - Pipeline by Immunomic Therapeutics, Inc., H2 2015 29
Pollen Allergy - Pipeline by Japan Tobacco Inc., H2 2015 30
Pollen Allergy - Pipeline by Laboratorios LETI S.L., H2 2015 31
Pollen Allergy - Pipeline by REGiMMUNE Corporation, H2 2015 32
Pollen Allergy - Pipeline by Roxall Medizin GmbH, H2 2015 33
Pollen Allergy - Pipeline by Shionogi & Co., Ltd., H2 2015 34
Pollen Allergy - Pipeline by Stallergenes S.A., H2 2015 35
Assessment by Monotherapy Products, H2 2015 36
Number of Products by Stage and Target, H2 2015 38
Number of Products by Stage and Mechanism of Action, H2 2015 39
Number of Products by Stage and Route of Administration, H2 2015 41
Number of Products by Stage and Molecule Type, H2 2015 43
Pollen Allergy Therapeutics - Recent Pipeline Updates, H2 2015 87
Pollen Allergy - Dormant Projects, H2 2015 96
Pollen Allergy - Dormant Projects (Contd..1), H2 2015 97
Pollen Allergy - Discontinued Products, H2 2015 98

List of Figures

Number of Products under Development for Pollen Allergy, H2 2015 11
Number of Products under Development for Pollen Allergy - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 13
Comparative Analysis by Late Stage Development, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Products, H2 2015 17
Assessment by Monotherapy Products, H2 2015 36
Number of Products by Top 10 Targets, H2 2015 37
Number of Products by Stage and Top 10 Targets, H2 2015 37
Number of Products by Top 10 Routes of Administration, H2 2015 40
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 40
Number of Products by Top 10 Molecule Types, H2 2015 42
Number of Products by Stage and Top 10 Molecule Types, H2 2015 42

Published By: Global Markets Direct
Product Code: Global Markets Direct12881


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we´┐Żll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: